Nokia Oyj
15.10.2026 16:00:00 CEST | Globenewswire | Press release
Changes in Nokia Corporation's own shares
Changes in Nokia Corporation's own shares
Nokia Corporation
Stock Exchange Release
15 October 2026 at 17:00 EEST
Changes in Nokia Corporation's own shares
Espoo, Finland – A total of 2 142 361 Nokia shares (NOKIA) held by the company were transferred today without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the incentive plans as announced on 2 October 2025.
The number of own shares held by Nokia Corporation following the transfer is 81 161 716.
About Nokia
Nokia is a global leader in connectivity infrastructure, enabling the AI supercycle. We build networks that connect intelligence and deliver a comprehensive connectivity solution across fixed, mobile, IP, optical, core, and data center networks. With security by design, AI-driven innovation, and AI-optimized architecture, Nokia delivers trusted infrastructure that enables AI to scale and advances connectivity to secure a brighter world.
Inquiries:
Nokia
Communications
Phone: +358 10 448 4900
Email: press.services@nokia.com
Maria Vaismaa, Vice President, Corporate Communications
Nokia
Investor Relations
Phone: +358 931 580 507
Email: investor.relations@nokia.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Norvault23.10.2026 16:29:06 CEST | Press release
NORVAULT AG extends Bacon Series 001 offer and tender timetable
XBiotech Inc.23.10.2026 15:17:07 CEST | Press release
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
Precede Biosciences, Inc.23.10.2026 15:15:00 CEST | Press release
Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
Golar LNG23.10.2026 14:16:21 CEST | Press release
Golar releases 2025 Environmental, Social and Governance report
Novartis Pharma AG23.10.2026 13:30:00 CEST | Press release
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom